Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis
Abstract To better understand the efficacy of intravitreal dexamethasone implant (Ozurdex) versus antivascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular edema (DME). A systematic review and meta-analysis. The study included randomized control trials (RCTs) and...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-34673-z |
| _version_ | 1797827521278902272 |
|---|---|
| author | Sheng-Chu Chi Yi-No Kang Yi-Ming Huang |
| author_facet | Sheng-Chu Chi Yi-No Kang Yi-Ming Huang |
| author_sort | Sheng-Chu Chi |
| collection | DOAJ |
| description | Abstract To better understand the efficacy of intravitreal dexamethasone implant (Ozurdex) versus antivascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular edema (DME). A systematic review and meta-analysis. The study included randomized control trials (RCTs) and non-randomized control trials (Non-RCTs) before December 2021 that compare the efficacy of Ozurdex-related therapyand anti-VEGF therapy. We searched PubMed, Cochrane Library, and EMBASE. The quality of the included studies was assessed carefully. 30 studies were included. Regarding BCVA change, the overall result revealed no significant differences between Ozurdex and anti-VEGF therapies in patients with nonresistant DME, but Ozurdex group had significantly more VA improvement than anti-VEGF therapies in patients with resistant DME (MD 0.12, 95% CI 0.02–0.21). In terms of central retinal thickness (CRT) decrease, there was a significant difference between Ozurdex therapy and anti-VEGF therapy in patients with nonresistant DME (MD 48.10, 95% CI 19.06–77.13) and resistant DME (MD 65.37, 95% CI 3.62–127.13). Overall, Ozurdex therapy resulted in significantly greater VA improvement and CRT decrease than anti-VEGF therapy in resistant DME patients. Ozurdex therapy was not inferior to anti-VEGF therapy in patients with nonresistant DME. |
| first_indexed | 2024-04-09T12:50:41Z |
| format | Article |
| id | doaj.art-98f10bb2e9cd4d9b9f65df5f7e270f92 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-09T12:50:41Z |
| publishDate | 2023-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-98f10bb2e9cd4d9b9f65df5f7e270f922023-05-14T11:16:15ZengNature PortfolioScientific Reports2045-23222023-05-0113111110.1038/s41598-023-34673-zEfficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysisSheng-Chu Chi0Yi-No Kang1Yi-Ming Huang2Department of Ophthalmology, Faculty of Medicine, Taipei Veterans General HospitalEvidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical UniversityDepartment of Ophthalmology, Faculty of Medicine, Taipei Veterans General HospitalAbstract To better understand the efficacy of intravitreal dexamethasone implant (Ozurdex) versus antivascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular edema (DME). A systematic review and meta-analysis. The study included randomized control trials (RCTs) and non-randomized control trials (Non-RCTs) before December 2021 that compare the efficacy of Ozurdex-related therapyand anti-VEGF therapy. We searched PubMed, Cochrane Library, and EMBASE. The quality of the included studies was assessed carefully. 30 studies were included. Regarding BCVA change, the overall result revealed no significant differences between Ozurdex and anti-VEGF therapies in patients with nonresistant DME, but Ozurdex group had significantly more VA improvement than anti-VEGF therapies in patients with resistant DME (MD 0.12, 95% CI 0.02–0.21). In terms of central retinal thickness (CRT) decrease, there was a significant difference between Ozurdex therapy and anti-VEGF therapy in patients with nonresistant DME (MD 48.10, 95% CI 19.06–77.13) and resistant DME (MD 65.37, 95% CI 3.62–127.13). Overall, Ozurdex therapy resulted in significantly greater VA improvement and CRT decrease than anti-VEGF therapy in resistant DME patients. Ozurdex therapy was not inferior to anti-VEGF therapy in patients with nonresistant DME.https://doi.org/10.1038/s41598-023-34673-z |
| spellingShingle | Sheng-Chu Chi Yi-No Kang Yi-Ming Huang Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis Scientific Reports |
| title | Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis |
| title_full | Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis |
| title_short | Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis |
| title_sort | efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema a systematic review and meta analysis |
| url | https://doi.org/10.1038/s41598-023-34673-z |
| work_keys_str_mv | AT shengchuchi efficacyandsafetyprofileofintravitrealdexamethasoneimplantversusantivascularendothelialgrowthfactortreatmentindiabeticmacularedemaasystematicreviewandmetaanalysis AT yinokang efficacyandsafetyprofileofintravitrealdexamethasoneimplantversusantivascularendothelialgrowthfactortreatmentindiabeticmacularedemaasystematicreviewandmetaanalysis AT yiminghuang efficacyandsafetyprofileofintravitrealdexamethasoneimplantversusantivascularendothelialgrowthfactortreatmentindiabeticmacularedemaasystematicreviewandmetaanalysis |